Neomycin ( DrugBank: Neomycin )

3 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2
97	Ulcerative colitis	1
296	Biliary atresia	1

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03476317 (ClinicalTrials.gov)	July 12, 2018	8/1/2018	Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn Disease	Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Fluconazole	Children's Hospital of Philadelphia	University of Pennsylvania;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	6 Years	N/A	All	10	Phase 2	United States
2	NCT02765256 (ClinicalTrials.gov)	August 2016	2/5/2016	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn's Disease	Drug: Fluconazole;Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Promethazine;Drug: Fluconazole placebo	University of Pennsylvania	Children's Hospital of Philadelphia;Crohn's and Colitis Foundation	Completed	18 Years	75 Years	All	8	Phase 2	United States

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00355602 (ClinicalTrials.gov)	July 2006	21/7/2006	Antibiotics for the Treatment of Ulcerative Colitis	Use of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis Patients	Colitis, Ulcerative	Drug: Cefuroxime;Drug: Ciprofloxacin;Drug: Clarithromycin;Drug: Cotrimoxazole;Drug: Coamoxiclav;Drug: metronidazole;Drug: neomycin;Drug: rifaximin;Drug: Vancomycin;Drug: Doxycycline	University of Dundee	Tenovus Scotland	Completed	18 Years	79 Years	Both	40	N/A	United Kingdom

Clinical trials : 63 / Drugs : 65 - (DrugBank : 37) / Drug target genes : 45 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00166868 (ClinicalTrials.gov)	December 2003	12/9/2005	Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy	Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia	Biliary Atresia	Drug: Lactobacillus casei rhamnosus (Lcr35);Drug: Neomycin	National Taiwan University Hospital	NULL	Completed	4 Months	3 Years	Both	30	N/A	Taiwan